853 related articles for article (PubMed ID: 31678528)
41. Mesoporous manganese silicate coated silica nanoparticles as multi-stimuli-responsive T1-MRI contrast agents and drug delivery carriers.
Li X; Zhao W; Liu X; Chen K; Zhu S; Shi P; Chen Y; Shi J
Acta Biomater; 2016 Jan; 30():378-387. PubMed ID: 26602820
[TBL] [Abstract][Full Text] [Related]
42. Multifunctional metal-coordinated Co-assembled carrier-free nanoplatform based on dual-drugs for ferroptosis-mediated cocktail therapy of hepatocellular carcinoma growth and metastasis.
Zhao RR; Wu JH; Tong LW; Li JY; Lu YS; Shao JW
J Colloid Interface Sci; 2024 Apr; 660():257-276. PubMed ID: 38244494
[TBL] [Abstract][Full Text] [Related]
43. DN200434, an orally available inverse agonist of estrogen-related receptor γ, induces ferroptosis in sorafenib-resistant hepatocellular carcinoma.
Kim DH; Kim MJ; Kim NY; Lee S; Byun JK; Yun JW; Lee J; Jin J; Kim J; Chin J; Cho SJ; Lee IK; Choi YK; Park KG
BMB Rep; 2022 Nov; 55(11):547-552. PubMed ID: 36016501
[TBL] [Abstract][Full Text] [Related]
44. CRISPR screens uncover protective effect of PSTK as a regulator of chemotherapy-induced ferroptosis in hepatocellular carcinoma.
Chen Y; Li L; Lan J; Cui Y; Rao X; Zhao J; Xing T; Ju G; Song G; Lou J; Liang J
Mol Cancer; 2022 Jan; 21(1):11. PubMed ID: 34983546
[TBL] [Abstract][Full Text] [Related]
45. The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells.
Louandre C; Marcq I; Bouhlal H; Lachaier E; Godin C; Saidak Z; François C; Chatelain D; Debuysscher V; Barbare JC; Chauffert B; Galmiche A
Cancer Lett; 2015 Jan; 356(2 Pt B):971-7. PubMed ID: 25444922
[TBL] [Abstract][Full Text] [Related]
46. Fe-MnO
Huang D; Xu D; Chen W; Wu R; Wen Y; Liu A; Lin L; Lin X; Wang X
Biomed Pharmacother; 2023 May; 161():114431. PubMed ID: 36827713
[TBL] [Abstract][Full Text] [Related]
47. Improved anticancer efficacy of epirubicin by magnetic mesoporous silica nanoparticles: in vitro and in vivo studies.
Ansari L; Jaafari MR; Bastami TR; Malaekeh-Nikouei B
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):594-606. PubMed ID: 29688064
[TBL] [Abstract][Full Text] [Related]
48. ACSL4 is a predictive biomarker of sorafenib sensitivity in hepatocellular carcinoma.
Feng J; Lu PZ; Zhu GZ; Hooi SC; Wu Y; Huang XW; Dai HQ; Chen PH; Li ZJ; Su WJ; Han CY; Ye XP; Peng T; Zhou J; Lu GD
Acta Pharmacol Sin; 2021 Jan; 42(1):160-170. PubMed ID: 32541921
[TBL] [Abstract][Full Text] [Related]
49. Dihydroartemisinin enhances the inhibitory effect of sorafenib on HepG2 cells by inducing ferroptosis and inhibiting energy metabolism.
Cui Z; Wang H; Li S; Qin T; Shi H; Ma J; Li L; Yu G; Jiang T; Li C
J Pharmacol Sci; 2022 Jan; 148(1):73-85. PubMed ID: 34924133
[TBL] [Abstract][Full Text] [Related]
50. Manganese porphyrin-based metal-organic framework for synergistic sonodynamic therapy and ferroptosis in hypoxic tumors.
Xu Q; Zhan G; Zhang Z; Yong T; Yang X; Gan L
Theranostics; 2021; 11(4):1937-1952. PubMed ID: 33408790
[TBL] [Abstract][Full Text] [Related]
51. Low-density lipoprotein decorated silica nanoparticles co-delivering sorafenib and doxorubicin for effective treatment of hepatocellular carcinoma.
Ye J; Zhang R; Chai W; Du X
Drug Deliv; 2018 Nov; 25(1):2007-2014. PubMed ID: 30799656
[TBL] [Abstract][Full Text] [Related]
52. Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis.
Sun X; Niu X; Chen R; He W; Chen D; Kang R; Tang D
Hepatology; 2016 Aug; 64(2):488-500. PubMed ID: 27015352
[TBL] [Abstract][Full Text] [Related]
53. Design And Characterisation Of Novel Sorafenib-Loaded Carbon Nanotubes With Distinct Tumour-Suppressive Activity In Hepatocellular Carcinoma.
Elsayed MM; Mostafa ME; Alaaeldin E; Sarhan HA; Shaykoon MS; Allam S; Ahmed AR; Elsadek BE
Int J Nanomedicine; 2019; 14():8445-8467. PubMed ID: 31754301
[TBL] [Abstract][Full Text] [Related]
54. BHQ-Cyanine-Based "Off-On" Long-Circulating Assembly as a Ferroptosis Amplifier for Cancer Treatment: A Lipid-Peroxidation Burst Device.
Sang M; Luo R; Bai Y; Dou J; Zhang Z; Liu F; Feng F; Liu W
ACS Appl Mater Interfaces; 2019 Nov; 11(46):42873-42884. PubMed ID: 31553151
[TBL] [Abstract][Full Text] [Related]
55. Co-delivery of Sorafenib and CRISPR/Cas9 Based on Targeted Core-Shell Hollow Mesoporous Organosilica Nanoparticles for Synergistic HCC Therapy.
Zhang BC; Luo BY; Zou JJ; Wu PY; Jiang JL; Le JQ; Zhao RR; Chen L; Shao JW
ACS Appl Mater Interfaces; 2020 Dec; 12(51):57362-57372. PubMed ID: 33301289
[TBL] [Abstract][Full Text] [Related]
56. Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co-delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex.
Zhao R; Li T; Zheng G; Jiang K; Fan L; Shao J
Biomaterials; 2017 Oct; 143():1-16. PubMed ID: 28755539
[TBL] [Abstract][Full Text] [Related]
57. Tiliroside targets TBK1 to induce ferroptosis and sensitize hepatocellular carcinoma to sorafenib.
Yang C; Lu T; Liu M; Yuan X; Li D; Zhang J; Zhou L; Xu M
Phytomedicine; 2023 Mar; 111():154668. PubMed ID: 36657316
[TBL] [Abstract][Full Text] [Related]
58. Interventing mitochondrial PD-L1 suppressed IFN-γ-induced cancer stemness in hepatocellular carcinoma by sensitizing sorafenib-induced ferroptosis.
Li T; Huang HY; Qian B; Wang WH; Yuan Q; Zhang HY; He J; Ni KJ; Wang P; Zhao ZY; He JL; Fu SW; Xu L; Lin YC; Lin ZN
Free Radic Biol Med; 2024 Feb; 212():360-374. PubMed ID: 38171407
[TBL] [Abstract][Full Text] [Related]
59. Modulating the site-specific oral delivery of sorafenib using sugar-grafted nanoparticles for hepatocellular carcinoma treatment.
Tunki L; Kulhari H; Vadithe LN; Kuncha M; Bhargava S; Pooja D; Sistla R
Eur J Pharm Sci; 2019 Sep; 137():104978. PubMed ID: 31254645
[TBL] [Abstract][Full Text] [Related]
60. pH-Responsive Sorafenib/Iron-Co-Loaded Mesoporous Polydopamine Nanoparticles for Synergistic Ferroptosis and Photothermal Therapy.
Liu S; Liu Y; Chang Q; Celia C; Deng X; Xie Y
Biomacromolecules; 2024 Jan; 25(1):522-531. PubMed ID: 38087829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
